Multiple Myeloma (MM) has seen rapid innovation over the past decade. New therapies are extending survival, reshaping treatment pathways, and creating new possibilities for patients. Yet the evidence frameworks we rely on have not kept pace. National datasets record admissions and prescriptions, but they are silent on what matters most: fatigue, pain, anxiety, sleep disruption, and the profound differences in symptom burden that patients carry every day. Without this view, we risk turning clinical breakthroughs into missed opportunities.
Sanius Health’s work in MM shows this clearly. In an early cohort, Sanius captured more than 6,000 datapoints in a single month, spanning sleep, activity, and symptom reporting. Weakness, drowsiness, and pain emerged as the most severe symptoms, cutting across the patient population. But it was among younger patients that the picture became even more striking: lower quality of life scores, greater severity across gastrointestinal and psychological symptoms, and more pronounced activity limitations – yet higher physical activity and sleep quality recorded by wearables. The mismatch between outward resilience and internal burden is stark, and it is invisible in the datasets that currently shape care and access decisions.
At EHA this year, Sanius presented these insights as part of a commitment to building a new infrastructure for MM evidence. By uniting continuous patient-reported outcomes with biometric monitoring through the MyMM ecosystem, Sanius are capturing the lived reality of disease burden in ways that can directly inform smarter therapeutic strategies and more equitable care pathways. Later this year, the organisation will expand this work at IMS and ISPOR with longer-term follow-up, showing not just what symptoms patients experience, but how they evolve across therapies and time.
But evidence alone is not enough. Patients need tangible support today, particularly as novel pathways like bispecific initiation bring new complexities and risks. As such, Sanius have built a live Patient Support Programme in MM, combining remote monitoring with wraparound coaching and escalation pathways. This model supports ambulatory pathway preparation and aims to help keep patients safe at home, reduce unnecessary hospital burden, and give clinical teams confidence that they can extend reach without adding workload. For patients, it means continuity and confidence; for partners, it creates a scalable infrastructure to deploy new therapies safely, equitably, and sustainably.
The challenge ahead is clear. Survival curves tell us progress is being made, but they do not tell us if patients are living well. The future of MM must be defined not only by extending life, but by improving its quality – day by day, line by line, and across every patient journey. That is the standard Sanius are working towards, and the reason the organisation will continue to push outcomes, research, and patient support further, together.
To learn more about Sanius’ work in accelerating therapies and access in Multiple Myeloma, visit: www.saniushealth.com or get in touch with us at hello@saniushealth.com.
